UAE Diabetes Market Opportunity Analysis 2018
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
UAE, with one of the highest rates of Type 2 diabetes represents significant societal costs, in relation to morbidity, mortality and also lost productivity coupled with a huge burden on the healthcare system. It has been observed that the high prevalence of diabetes in the UAE is gradually taking its toll on the overall health of the nation and also risking the country’s economic well-being.
The total number of diabetes patients in UAE were e estimated around 0.75 Million in 2013. With factors such as obesity, rising sedentary lifestyles and unhealthy diet acting in full force, it is expected that the number of diabetic patients in the UAE would grow at a CAGR of 4%-6%, which is double the growth rate of the global market. The number of diabetics in the UAE is expected to surpass 0.85 million by 2018.
The production of diabetes devices is not significant in the UAE. Only basic items such as syringes are manufactured in the UAE. Though the government is encouraging private entities and other public companies to increase the local domestic production sector, but the major hurdle is that UAE is not well equipped and does not posses the required capability to produce any high-tech equipment. The country is thus a net importer of devices used for diabetes care.
“UAE Diabetes Market Opportunity Analysis 2018” gives comprehensive insight on following aspects related to pharmaceutical market:
UAE, with one of the highest rates of Type 2 diabetes represents significant societal costs, in relation to morbidity, mortality and also lost productivity coupled with a huge burden on the healthcare system. It has been observed that the high prevalence of diabetes in the UAE is gradually taking its toll on the overall health of the nation and also risking the country’s economic well-being.
The total number of diabetes patients in UAE were e estimated around 0.75 Million in 2013. With factors such as obesity, rising sedentary lifestyles and unhealthy diet acting in full force, it is expected that the number of diabetic patients in the UAE would grow at a CAGR of 4%-6%, which is double the growth rate of the global market. The number of diabetics in the UAE is expected to surpass 0.85 million by 2018.
The production of diabetes devices is not significant in the UAE. Only basic items such as syringes are manufactured in the UAE. Though the government is encouraging private entities and other public companies to increase the local domestic production sector, but the major hurdle is that UAE is not well equipped and does not posses the required capability to produce any high-tech equipment. The country is thus a net importer of devices used for diabetes care.
“UAE Diabetes Market Opportunity Analysis 2018” gives comprehensive insight on following aspects related to pharmaceutical market:
- Market Overview
- Diabetes Prevalence
- Diabetes Drug Market
- Insulin Delivery Devices Market
- Glucose Monitoring Devices Market
- Diabetes Market Dynamics
1. UAE DIABETES MARKET OVERVIEW
1.1 Market Overview
1.2 Diabetes Incidence
2. UAE DIABETES MARKET DYNAMICS
2.1 Market Drivers
2.2 Challenges to be Resolved
2.3 Future Opportunities
3. UAE DIABETES DRUG MARKET
3.1 Oral
3.2 Insulin
4. UAE INSULIN DELIVERY DEVICES MARKET
4.1 Pens
4.2 Syringes
5. UAE GLUCOSE MONITORING DEVICES MARKET
6. COMPETITIVE MARKET
6.1 Gulf Pharmaceutical Industries (Julphar Diabetes)
6.2 Eli Lilly
6.3 Novo Nordisk
6.4 Medysinal Fze
6.5 Sanofi-Aventis
1.1 Market Overview
1.2 Diabetes Incidence
2. UAE DIABETES MARKET DYNAMICS
2.1 Market Drivers
2.2 Challenges to be Resolved
2.3 Future Opportunities
3. UAE DIABETES DRUG MARKET
3.1 Oral
3.2 Insulin
4. UAE INSULIN DELIVERY DEVICES MARKET
4.1 Pens
4.2 Syringes
5. UAE GLUCOSE MONITORING DEVICES MARKET
6. COMPETITIVE MARKET
6.1 Gulf Pharmaceutical Industries (Julphar Diabetes)
6.2 Eli Lilly
6.3 Novo Nordisk
6.4 Medysinal Fze
6.5 Sanofi-Aventis
LIST OF FIGURES
Figure 1-1: Total Medical Cost for All Types of Diabetes (US$ Million), 2012-2018
Figure 1-2: Medical Cost for Type 2 Diabetes (US$ Million), 2012-2018
Figure 1-3: Medical Cost for Type-1 Diabetes (US$ Million), 2012-2018
Figure 1-4: Medical Cost for Undiagnosed Diabetes (US$ Million), 2012-2018
Figure 1-5: Diabetes Prevalence (%), 2012 & 2030
Figure 1-6: UAE v/s GCC Countries Diabetes Prevalence, 2012
Figure 1-7: Number of Type 2 Diabetes Cases (‘000), 2012-2018
Figure 1-8: Number of Type 1 Diabetes Cases (‘000), 2012-2018
Figure 1-9: Number of Undiagnosed Diabetes Cases (‘000), 2012-2018
Figure 1-10: Type-2 Diabetes Prevalence in Age Group 20-79 (%)
Figure 2-1: Factor Driving Diabetes Prevalence
Figure 2-2: Challenges for Diabetes Market
Figure 3-1: Oral Insulin Market (US$ Million), 2012-2018
Figure 3-2: Insulin Device (US$ Million), 2012-2018
Figure 4-1: Insulin Pen Market (US$ Million), 2012-2018
Figure 4-2: Insulin Syringe Market (US$ Million), 2012-2018
Figure 5-1: Glucose Monitoring Devices Market (US$ Million), 2012-2018
Figure 1-1: Total Medical Cost for All Types of Diabetes (US$ Million), 2012-2018
Figure 1-2: Medical Cost for Type 2 Diabetes (US$ Million), 2012-2018
Figure 1-3: Medical Cost for Type-1 Diabetes (US$ Million), 2012-2018
Figure 1-4: Medical Cost for Undiagnosed Diabetes (US$ Million), 2012-2018
Figure 1-5: Diabetes Prevalence (%), 2012 & 2030
Figure 1-6: UAE v/s GCC Countries Diabetes Prevalence, 2012
Figure 1-7: Number of Type 2 Diabetes Cases (‘000), 2012-2018
Figure 1-8: Number of Type 1 Diabetes Cases (‘000), 2012-2018
Figure 1-9: Number of Undiagnosed Diabetes Cases (‘000), 2012-2018
Figure 1-10: Type-2 Diabetes Prevalence in Age Group 20-79 (%)
Figure 2-1: Factor Driving Diabetes Prevalence
Figure 2-2: Challenges for Diabetes Market
Figure 3-1: Oral Insulin Market (US$ Million), 2012-2018
Figure 3-2: Insulin Device (US$ Million), 2012-2018
Figure 4-1: Insulin Pen Market (US$ Million), 2012-2018
Figure 4-2: Insulin Syringe Market (US$ Million), 2012-2018
Figure 5-1: Glucose Monitoring Devices Market (US$ Million), 2012-2018
